Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 15/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411063 | 0.83 | PIK3CA (0.49) | TBK1IKBKEDGAT1MTORL3MBTL1 | |
| SCHEMBL2177453 | 0.81 | PIK3CA (0.47) | TBK1IKBKEDGAT1MTORL3MBTL1 | |
| SCHEMBL2520077 | 0.77 | TRPM8 (0.53) | L3MBTL1 | |
| SCHEMBL2177742 | 0.76 | IKBKE (0.41) | TBK1IKBKEDGAT1MTORL3MBTL1 | |
| SCHEMBL28518770 | 0.74 | LMNA (0.50) | MTOR | |
| SCHEMBL29301634 | 0.73 | MAPT (0.61) | DGAT1MTOR | |
| SCHEMBL18039588 | 0.72 | TRPM8 (0.42) | L3MBTL1 | |
| SCHEMBL18394475 | 0.72 | USP2 (0.44) | MTORL3MBTL1PIK3CA | |
| SCHEMBL7453654 | 0.72 | LMNA (0.55) | — | |
| SCHEMBL12079327 | 0.72 | MTOR (0.35) | MTORL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | TBK1 301/4885IKBKE 93/4885DGAT1 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.